#South Korea #Seongnam #Hansoh Pharma #Merigolix #TiumBio

TiumBio's Collaboration with Hansoh Pharma

In a significant advancement for the field of assisted reproductive technology (ART), TiumBio, a clinical-stage biopharmaceutical company, has announced that its partner, Hansoh Pharma, is expanding the clinical indications for Merigolix (HS-10518). This oral gonadotropin-releasing hormone (GnRH) receptor antagonist has gained traction for its pivotal role in improving the outcomes of ART cycles by effectively addressing premature luteinizing hormone (LH) surges.

Overview of Merigolix

Merigolix, developed for the inhibition of premature LH surges during controlled ovarian stimulation (COS), is particularly noteworthy as it is an orally administered medication. Traditionally, GnRH products have been limited to injections, which can come with discomfort and higher costs. This new option could significantly enhance patient experience during treatment cycles, addressing a major unmet need in the ART landscape.

Importance of the IND Approval

On March 20, 2025, Hansoh Pharma received approval for an Investigational New Drug (IND) application that targets ART, effectively expanding the developmental focus of Merigolix. According to Dr. Hun-Taek Kim, CEO of TiumBio, this developmental choice is particularly impactful due to ART's shorter treatment duration compared to other indications, facilitating expedited development timelines.

The approval not only signifies a leap forward for Merigolix but also reflects a growing understanding of patient needs in fertility treatments. With COS being a critical component of ART cycles, the introduction of Merigolix could potentially reduce cycle cancellation rates and ultimately improve the pregnancy rates per cycle.

The Science Behind It

The mechanism by which Merigolix operates involves the suppression of premature LH secretion, which can complicate IVF and ART procedures. With the enhanced ability to control LH surges, clinicians can tailor treatments more efficiently, benefiting women who experience various ovarian responses. This could lead to significant increases in successful pregnancies, marking a transformative shift in reproductive medicine.

TiumBio's Vision and Future Prospects

TiumBio, traded on KOSDAQ under the stock number 321550, is on a mission to bring innovative therapies to patients suffering from rare and incurable diseases. In addition to Merigolix, the company is also developing other promising treatments, such as TU2218 and TU7710, aimed at different health challenges, including cancer treatment and hemophilia.

As the landscape of reproductive health evolves, TiumBio's partnership with Hansoh Pharma stands as a beacon of hope for many. With its commitment to research and innovation, TiumBio continues to push the boundaries of possibility in the biopharmaceutical industry. The expansion of Merigolix's indications highlights not only their dedication to patient care but also their strategic positioning within the competitive global market for fertility treatments.

In conclusion, the advancements surrounding Merigolix tell a compelling story about the future of ART. As patient needs continue to evolve, innovative solutions like these foster optimism in reproductive health, ensuring that countless individuals have opportunities to achieve their dreams of starting a family.